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Abstract
Background: There are still controversies about the integration of breast cancer as a part of the
disease spectrum in Lynch syndrome.
Methods: A regular follow-up of a Lebanese pedigree with Lynch syndrome due to a point
mutation of MSH2 gene at the splice donor site of intron 3 started in 1996.
Results: A 26-year-old pregnant woman, mutation carrier, developed an aggressive breast cancer,
refractory to standard chemotherapy regimens. The microsatellite analysis of the tumor showed
an unstable pattern for markers BAT25 and BAT26. The immunohistochemical staining was
negative for MSH2 and MSH6 and normal for MLH1 and PMS6 enzymes.
Conclusion: The segregation of the mutation with the disease phenotype and these results
suggest that MSH2 inactivation may be involved in the accelerated breast carcinogenesis and might
be considered in the cancer screening program.
Background
The identification of the germline mutation in a Lynch
syndrome family allows mutation carriers to be included
in lifesaving cancer surveillance programs [1]. The occur-
rence of cancer of a type that is atypical for the hereditary
cancer syndrome in a family makes the interpretation of
the pedigree difficult. It is not uncommon to see Lynch
syndrome pedigrees with breast cancer (BC). However,
there is no agreement as to whether breast cancer is part of
the disease spectrum [2-4]. Most genetic and immunohis-
tochemical studies on familial and sporadic breast cancers
did not evoke any strong relationship with the mismatch
repair (MMR) gene defect. Muller et al [3] found that syn-
chronous and metachronous breast cancers from Lynch
syndrome families usually arise sporadically because they
display a stable micro satellite pattern and normal MMR
protein expression. Wong et al [5] in an extensive screen-
ing study of 59 multiple-case BC families; did not identify
any genetic abnormality that might implicate MSH2 as a
BC susceptibility gene. Khilko et al [6] in an immunohis-
tochemical staining of 211 BC specimens did not show
any loss of MMR protein expression. Here, we report a
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Lebanese Lynch syndrome family (figure 1) with a case of
early-onset breast cancer, in which the microsatellite
instability (MSI) and the immunohistochemical (IHC)
studies suggest strongly a relationship with the MSH2
gene defect.
Methods
Seventeen carriers of MSH2 gene point mutation,
IVS3+1G>A, were included in a regular surveillance pro-
gram. An eight-year follow-up result of this family was
published in a previous report [7]. The MSI analysis was
performed after PCR amplification of tumor and normal
surrounding borders DNA at eight loci containing mono-
nucleotide and dinucleotide repeated sequences using flu-
orescent specific primers for each locus: BAT-25, BAT-26,
D2S123, D17S250, RIITGFβ, NR21, NR22, and NR24.
The PCR products were electrophoresed for three hours in
an Applied Biosystems (ABI) Prism sequencer. Data were
collected using the GeneScan program for fragment anal-
ysis and alterations in the micro satellites were detected by
comparing normal tissue and tumor tissue DNA strands
in neighboring lanes. The IHC staining was also per-
formed in paraffin embedded tumor and normal tissues
for MSH2, MLH1, MSH6, PMS2, CK7 and CK20. Testing
for germline BRCA1, BRCA2 and TP53 mutations was not
available in our clinic.
Results and discussion
Although no new colorectal or gynecological tumor was
screen-detected since the previous update on this pedigree
[7] an unforeseen breast cancer in a 26 years old pregnant
female (III 34) has occurred. No family history of breast
cancer was noted in any branch of the family. No breast or
ovarian cancer was known in any paternal family member
of this patient. Screening for breast cancer was not part of
our surveillance program, since there was no reason to
suspect such a tumor as early as 26 years and during preg-
nancy. This patient who carries the MSH2 germline muta-
tion developed an infiltrating ductal carcinoma of the left
breast with distant metastases at the first presentation. The
tumor was of high histological grade with negative estro-
gen receptors and positive c-erb B2 oncoprotein expres-
sion. This metastatic breast cancer did not respond to
standard chemotherapy regimens including Trastuzumab,
Taxanes and Doxorubicin.
MSI was present in 4 out of 8 loci in the tumor specimen.
The IHC analysis revealed a negative expression for CK20,
Analysis of the Lebanese pedigree with Lynch syndrome due to MSH2 gene mutation Figure 1
Analysis of the Lebanese pedigree with Lynch syndrome due to MSH2 gene mutation.
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MSH2 and MSH6 and a positive expression for CK7 and
MLH1 proteins, which confirm the mammary origin of
the tumor and the role of the defective MSH2 gene in the
pathogenesis (Tables 1 and 2).
MMR gene mutation carriers are at high risk of developing
Lynch syndrome-related cancers. Some of them develop
sporadic cancers due to exposure to non-genetic risk fac-
tors, polymorphisms in other genes and chance. These
sporadic tumors may include breast cancer and usually
exhibit stable microsatellite patterns and normal MMR
protein expressions. The absence of an MSI-high pattern
in a breast cancer specimen from MSH2 mutation carrier
indicates that the development of such a tumor is unre-
lated to MMR gene impairment, despite the presence of
the constitutional mutation. In contrast, a microsatellite
instable early onset breast cancer that did not express the
MSH2 protein in IHC and occurs in a proven MMR gene
mutation carrier is highly suggestive of its belonging to
the tumor spectrum of the disease [8,9]. Still, there is cur-
rently no evidence to suggest that, in general, female
Lynch syndrome mutation carriers are at a strongly
increased risk to develop breast cancer. In some cases, as
we and others have shown, deficient DNA mismatch
repair can contribute to breast cancer development in
Lynch syndrome families. These findings do not necessar-
ily imply that the underlying germline MMR mutation
was also the strongest and most important risk factor in
those breast cancer cases. Other genetic and non-genetic
risk factors may have contributed and therefore all close
relatives of breast cancer patients in Lynch syndrome fam-
ilies, including the relatives that do not carry the MMR
mutation, might have an increased breast cancer risk. Test-
ing for other germline mutation, e.g. of BRCA1, BRCA2
and possibly TP53, should be considered, especially in
early-onset cases and unfortunately, we cannot exclude
the presence of such mutation in our patient. It is not yet
possible to accurately predict breast cancer risk for MMR
mutation carriers in families with one or more cases of
breast cancer. In lynch syndrome families; one might con-
sider breast cancer surveillance for close female relatives
of breast cancer cases, especially of those cases with early-
onset breast cancer. Such surveillance might follow the
guidelines for families with breast cancer and absence of
detectable germline mutations in known hereditary breast
cancer-associated genes. Although the efficacy of the sur-
veillance program in reducing colorectal cancer mortality
in Lynch syndrome has been proven, the benefit of breast
cancer screening in selected Lynch syndrome families
remains to be seen. In our opinion, cancers occurring in
Lynch syndrome families which are not typical for that
syndrome should undergo MSI analysis and immunos-
taining for the MMR gene protein expression in order to
better assess the phenotype-genotype relationship and
ultimately change the surveillance guidelines accordingly.
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Table 1: Microsatellite Instability (MSI) test results.
Locus Stable Unstable
BAT-25 ×
BAT-26 ×
D2S123/AFM093X43 ×
D17S250/MFd ×
RIITGFβ ×
NR21 ×
NR22 ×
NR24 ×
Table 2: Immunohistochemical (IHC) test results.
Tumor tissue Normal tissue
hMLH1 Positive Positive
hMSH2 Negative Positive
hMSH6 Negative Positive
PMS2 Positive Positive
CK7 Positive
CK20 Negative